A Phase 4 interventional study of Diacerhein in Osteoarthritis, sponsored by Laboratoires NEGMA. Completed at 1 site in Canada. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-03-04.
Sponsored by Laboratoires NEGMA (part of Wockhardt) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.
Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 90th largest by planned enrollment of the 176 interventional ones that give a count, is one of 11 that started in 2007, is one of 13 in phase 4, and was the 21st registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
FUSMobile Inc. · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 50+
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 31 · Phase 4 13
First in 1996; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 98 across the 176 interventional studies, 132 across the 29 observational. Of the 130 that completed or were terminated, 37 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 205 have an industry lead sponsor. The 10 most frequent:
This study is registered under Laboratoires NEGMA, one of the names counted as Wockhardt. Under that name alone:
Laboratoires NEGMA is the lead sponsor of 4 studies on the registry; none are open to participants now.
Wockhardt has 2 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
15 of the studies in Osteoarthritis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06966206Phase 3St. Joseph's Healthcare HamiltonMultiprofen-CC to Reduce Pain in Hand Arthritis | 2026-12-31 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT04634773Ottawa Hospital Research InstituteUnravelling the Etiology of Shoulder Osteoarthritis | 2026-12 |
| NCT06681142University of AlbertaPharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis | 2026-12-01 |
| NCT07178951FUSMobile Inc.Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 205 studies in Osteoarthritis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Some inflammation mediators, notably IL-1, are implied in the joint degeneration phenomena of osteoarthritis. The aim of this study is to confirm in vivo the favourable effect of diacerhein on IL-1 and also to appreciate its effect on other synovial inflammation mediators.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Synovial concentration of IL-1
Synovial concentration of IL-6
WOMAC
The record gives a start of Mar 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diacerein